Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
Retrieved on:
Giovedì, Maggio 25, 2023
The aggregate gross proceeds from this offering are expected to be approximately $16.5 million, prior to deducting placement agent fees and estimated offering expenses.
Key Points:
- The aggregate gross proceeds from this offering are expected to be approximately $16.5 million, prior to deducting placement agent fees and estimated offering expenses.
- The Company intends to use the proceeds from the offering to fund product development and regulatory activities, and for working capital and general corporate purposes.
- The offering is expected to close on or about May 30, 2023, subject to customary closing conditions.
- Current Achieve investors, including investors in Dialectic Life Sciences and various entities affiliated with the Hunt Family, as well as members of Achieve’s management, are participating in this transaction.